[go: up one dir, main page]

MA52934A - Composés inhibiteurs de l'oga - Google Patents

Composés inhibiteurs de l'oga

Info

Publication number
MA52934A
MA52934A MA052934A MA52934A MA52934A MA 52934 A MA52934 A MA 52934A MA 052934 A MA052934 A MA 052934A MA 52934 A MA52934 A MA 52934A MA 52934 A MA52934 A MA 52934A
Authority
MA
Morocco
Prior art keywords
inhibitor compounds
oga inhibitor
oga
compounds
inhibitor
Prior art date
Application number
MA052934A
Other languages
English (en)
Inventor
José Manuel Bartolomé-Nebreda
Susana Conde-Ceide
Francisca Delgado-Jiménez
Carlos Manuel Martinez-Viturro
Andrés Avelino Trabanco-Suárez
Ramiro Juan Antonio Vega
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA52934A publication Critical patent/MA52934A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA052934A 2018-06-20 2019-06-20 Composés inhibiteurs de l'oga MA52934A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18382447 2018-06-20

Publications (1)

Publication Number Publication Date
MA52934A true MA52934A (fr) 2021-04-28

Family

ID=62784074

Family Applications (2)

Application Number Title Priority Date Filing Date
MA052934A MA52934A (fr) 2018-06-20 2019-06-20 Composés inhibiteurs de l'oga
MA052935A MA52935A (fr) 2018-06-20 2019-06-20 Composés inhibiteurs d'oga

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA052935A MA52935A (fr) 2018-06-20 2019-06-20 Composés inhibiteurs d'oga

Country Status (9)

Country Link
US (2) US20210277015A1 (fr)
EP (2) EP3810593A1 (fr)
JP (2) JP2021527659A (fr)
CN (2) CN112292377A (fr)
AU (2) AU2019289968A1 (fr)
CA (2) CA3102462A1 (fr)
MA (2) MA52934A (fr)
TW (2) TW202012392A (fr)
WO (2) WO2019243526A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3585790A1 (fr) * 2017-02-27 2020-01-01 Janssen Pharmaceutica NV Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga
WO2021094312A1 (fr) * 2019-11-11 2021-05-20 Janssen Pharmaceutica Nv Composés inhibiteurs d'oga contenant de la pyrrolidine et de la bicyclohétéroaryle
JP2025510646A (ja) 2022-03-14 2025-04-15 スラップ ファーマシューティカルズ エルエルシー 多環式化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201701315VA (en) * 2014-08-28 2017-03-30 Asceneuron Sa Glycosidase inhibitors
JP2019519582A (ja) * 2016-06-29 2019-07-11 オリオン コーポレーション ベンゾジオキサン誘導体およびその医薬用途
WO2018109202A1 (fr) * 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Composés inhibiteurs d'oga monocyclique

Also Published As

Publication number Publication date
EP3810594A1 (fr) 2021-04-28
MA52935A (fr) 2021-04-28
JP2021528413A (ja) 2021-10-21
EP3810593A1 (fr) 2021-04-28
AU2019289968A1 (en) 2020-12-17
CN112292377A (zh) 2021-01-29
CA3102458A1 (fr) 2019-12-26
AU2019289967A1 (en) 2020-12-17
WO2019243526A1 (fr) 2019-12-26
US20210300943A1 (en) 2021-09-30
TW202016093A (zh) 2020-05-01
CN112334461A (zh) 2021-02-05
CA3102462A1 (fr) 2019-12-26
WO2019243527A1 (fr) 2019-12-26
US20210277015A1 (en) 2021-09-09
TW202012392A (zh) 2020-04-01
JP2021527659A (ja) 2021-10-14

Similar Documents

Publication Publication Date Title
MA52939A (fr) Composés inhibiteurs d'oga
MA52942A (fr) Composés inhibiteurs d'oga
IL292753A (en) Compounds
EP3836923A4 (fr) Composés pyrrolo-dipyridine
MA52948A (fr) Composés
EP3941898C0 (fr) Composés fongicides
MA47420A (fr) Composés inhibiteurs d'oga
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
IL286833A (en) Compositions containing brazzein
EP3464275A4 (fr) Composés inhibiteurs de l'egfr
MA51669A (fr) Composés
EP3906026A4 (fr) Inhibiteurs irréversibles de l'interaction ménine-mll
EP3740487A4 (fr) Composés benzamide
DK4083038T3 (da) Pyridazinylthiazolcarboxamidforbindelse
EP4054724A4 (fr) Composés bifonctionnels
MA53003A (fr) Composés
MA46652A (fr) Polythérapie pour l'inhibition de c3
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3853210A4 (fr) Composés antibactériens
MA54521A (fr) Dérivés d'oxopyridine substitués
EP3476478A4 (fr) Composition pour l'élimination de composés soufrés
EP4077318A4 (fr) Composés
IL282231A (en) Compounds containing deuterium
MA52946A (fr) Composés